BXCL501 After Stress to Increase Recovery Success

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 29, 2025

Primary Completion Date

September 29, 2026

Study Completion Date

September 29, 2026

Conditions
Acute Stress ReactionAcute Stress DisorderPost-traumatic Stress Disorder
Interventions
DRUG

BXCL501 (dexmedetomidine HCl)

BXCL501 (dexmedetomidine HCl) taken sublingually (under the tongue) in the ED and at bedtime over 2 weeks.

DRUG

Placebo

Placebo taken sublingually (under the tongue) in the ED and at bedtime over 2 weeks.

Trial Locations (5)

22908

UVA University Hospital, Charlottesville

32209

University of Florida College of Medicine - Jacksonville, Jacksonville

63110

Washington University in St. Louis, St Louis

02903

Rhode Island Hospital, Providence

02906

The Miriam Hospital, Providence

All Listed Sponsors
collaborator

United States Department of Defense

FED

collaborator

Mclean Hospital

OTHER

collaborator

Washington University School of Medicine

OTHER

collaborator

University of Florida

OTHER

collaborator

Rhode Island Hospital

OTHER

collaborator

Vanderbilt University School of Medicine

OTHER

collaborator

Walter Reed Army Institute of Research (WRAIR)

FED

lead

University of North Carolina, Chapel Hill

OTHER